logo

CRDF’s Stock Market Puzzle: Piecing Together 2023’s Performance

A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 283.11%. However, over the past six months, we’ve seen a weaker performance of 342.97%. The price of CRDF fallen by 55.34% over the last 30 days. And in the last five days, it has fallen by -1.39%.

Cardiff Oncology Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $6.42 on 03/25/24, with the lowest value being $0.94 on 11/10/23.

52-week price history of CRDF Stock

The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Cardiff Oncology Inc’s current trading price is -11.68% away from its 52-week high, while its distance from the 52-week low is 503.19%. The stock’s price range for this period has been between $0.94 and $6.42. The Healthcare sector company’s shares saw a trading volume of about 1.88 million for the day, which was higher than the average daily volume of 1.67 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

Cardiff Oncology Inc (CRDF) has experienced a quarterly rise of 270.59% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 253.34M and boasts a workforce of 32 employees.

How Moving Averages and Trading Volume Data Work Together

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.29, with a change in price of +4.58. Similarly, Cardiff Oncology Inc recorded 1,116,556 in trading volume during the last 100 days, posting a change of +420.18%.

CRDF’s Debt-to-Equity Ratio: A Comprehensive Review

A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CRDF stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.

CRDF Stock Stochastic Average

As of today, the raw stochastic average of Cardiff Oncology Inc over the last 50 days is at 84.94%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 75.81%. Further, the company’s Stochastic %K and %D values for the last 20 days were 69.41% and 71.55%, respectively.